Moro Carlos Fernández, Selvam Arun Kumar, Ghaderi Mehran, Pimenoff Ville N, Gerling Marco, Bozóky Béla, Elduayen Soledad Pouso, Dillner Joakim, Björnstedt Mikael
Department of Laboratory Medicine, Division of Pathology F46, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden.
Department of Clinical Pathology and Cancer Diagnostics, Karolinska University Hospital, Stockholm, Sweden.
Front Oncol. 2022 Aug 18;12:965182. doi: 10.3389/fonc.2022.965182. eCollection 2022.
Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer. PDAC has a dismal prognosis and an inherent resistance to cytostatic drugs. The lack of reliable experimental models is a severe limitation for drug development targeting PDAC. We have employed a whole tissue culture model to explore the effect of redox-modulation by sodium selenite on the viability and growth of PDAC. Drug-resistant tumors are more vulnerable to redox-active selenium compounds because of high metabolic activity and redox imbalance. Sodium selenite efficiently and specifically reduced PDAC cell viability (p <0.02) (n=8) and decreased viable tumor cell outgrowth (p<0.05) while preserving non-neoplastic tissues. Major cellular responses (damaged tumor cells > 90%, tumor regression grades III-IV according to Evans) were observed for sodium selenite concentrations between 15-30 µM. Moreover, selenium levels used in this study were significantly below the previously reported maximum tolerated dose for humans. Transcriptome data analysis revealed decreased expression of genes known to drive PDAC growth and metastatic potential (CEMIP, DDR2, PLOD2, P4HA1) while the cell death-inducing genes (ATF3, ACHE) were significantly upregulated (p<0.0001). In conclusion, we report that sodium selenite has an extraordinary efficacy and specificity against drug-resistant pancreatic cancer in an organotypic slice culture model. Our organotypic tissue slice culture model can be used to test a variety of drug candidates for swift and reliable drug responses to individual PDAC cases.
胰腺导管腺癌(PDAC)是最常见的胰腺癌类型。PDAC预后不佳,对细胞抑制药物具有内在抗性。缺乏可靠的实验模型是靶向PDAC的药物开发的严重限制。我们采用了全组织培养模型来探索亚硒酸钠的氧化还原调节对PDAC活力和生长的影响。由于高代谢活性和氧化还原失衡,耐药肿瘤对氧化还原活性硒化合物更敏感。亚硒酸钠有效且特异性地降低了PDAC细胞活力(p<0.02)(n=8),并减少了存活肿瘤细胞的生长(p<0.05),同时保留了非肿瘤组织。观察到15-30µM亚硒酸钠浓度时出现主要细胞反应(受损肿瘤细胞>90%,根据埃文斯标准肿瘤消退分级为III-IV级)。此外,本研究中使用的硒水平显著低于先前报道的人类最大耐受剂量。转录组数据分析显示,已知驱动PDAC生长和转移潜能的基因(CEMIP、DDR2、PLOD2、P4HA1)表达降低,而诱导细胞死亡的基因(ATF3、ACHE)显著上调(p<0.0001)。总之,我们报告亚硒酸钠在器官型切片培养模型中对耐药胰腺癌具有非凡的疗效和特异性。我们的器官型组织切片培养模型可用于测试各种候选药物,以快速、可靠地获得针对个体PDAC病例的药物反应。